Nastech signs multi-compound feasibility agreement with Novo Nordisk

By E. Janene Geiss

Philadelphia, March 15 - Nastech Pharmaceutical Co. Inc. said Wednesday that it has entered into a multi-compound feasibility study agreement with Novo Nordisk A/S with respect to certain Novo Nordisk therapeutic compounds.

Specific compounds and indications were not announced. Financial and other terms were not disclosed, according to a company news release.

"Nastech is honored to be working with Novo Nordisk, a world-leader in therapies for metabolic disease. Novo Nordisk is known for its ethical standards and has participated in many innovative advances in medical practice," Steven C. Quay, chairman, president and chief executive officer of Nastech, said in the release.

Nastech is a Bothell, Wash., pharmaceutical company developing innovative products based on proprietary molecular biology-based drug delivery technologies.

Novo Nordisk is a Bagsvaerd, Denmark, health care company and a world leader in diabetes care. It manufactures and markets pharmaceutical products and services.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.